Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 4.32k | 82.22% |
| Gross profit | 4.32k | 82.22% |
| Net profit | -224.67k | 13.39% |
| EBITDA | -205.22k | 7.41% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €31.21m |
Number of shares | 106.48m |
52-week high/low | €0.46 - €0.21 |
| Dividends | No |
Beta | -0.31 |
P/E ratio | -31.11 |
PEG ratio | -0.90 |
P/B ratio | 78.20 |
P/S ratio | 1,608.56 |
Company profile
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
| Name | Biomark Diagnostics |
| CEO | Rashid Ahmed Maula Bux |
| Headquarters | Richmond,
bc Canada |
| Website | |
| IPO | 03/11/2014 |
| Employees | 9 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Cnq | BUX.CN |
Pnk | BMKDF |
Frankfurt | 20B.F |